MA52090A - Polythérapie - Google Patents

Polythérapie

Info

Publication number
MA52090A
MA52090A MA052090A MA52090A MA52090A MA 52090 A MA52090 A MA 52090A MA 052090 A MA052090 A MA 052090A MA 52090 A MA52090 A MA 52090A MA 52090 A MA52090 A MA 52090A
Authority
MA
Morocco
Prior art keywords
polytherapy
Prior art date
Application number
MA052090A
Other languages
English (en)
Inventor
Daniel P Gold
Original Assignee
Mei Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mei Pharma Inc filed Critical Mei Pharma Inc
Publication of MA52090A publication Critical patent/MA52090A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA052090A 2018-03-21 2019-03-20 Polythérapie MA52090A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862646314P 2018-03-21 2018-03-21

Publications (1)

Publication Number Publication Date
MA52090A true MA52090A (fr) 2021-04-21

Family

ID=67988025

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052090A MA52090A (fr) 2018-03-21 2019-03-20 Polythérapie

Country Status (16)

Country Link
US (1) US20210000838A1 (fr)
EP (1) EP3768258A4 (fr)
JP (1) JP2021517116A (fr)
KR (1) KR20200135439A (fr)
CN (1) CN112165939A (fr)
AU (1) AU2019238207A1 (fr)
BR (1) BR112020019082A2 (fr)
CA (1) CA3093847A1 (fr)
EA (1) EA202092154A1 (fr)
IL (1) IL277336A (fr)
MA (1) MA52090A (fr)
MX (1) MX2020009773A (fr)
SG (1) SG11202009137PA (fr)
TW (1) TW202002983A (fr)
WO (1) WO2019183226A1 (fr)
ZA (1) ZA202005661B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2608742C2 (ru) 2011-03-28 2017-01-23 ЭмИАй ФАРМА, ИНК. (альфа-замещенные аралкиламино- и гетероарилалкиламино)пиримидинил- и 1, 3, 5-триазинилбензимидазолы, их фармацевтические композиции и их применение в лечении пролиферативных заболеваний
WO2015035606A1 (fr) 2013-09-13 2015-03-19 Beigene, Ltd. Anticorps anti-pd1 et leur utilisation comme produits thérapeutiques et produits de diagnostic
EP3160505A4 (fr) 2014-07-03 2018-01-24 BeiGene, Ltd. Anticorps anti-pd-l1 et leur utilisation comme agents thérapeutiques et diagnostiques
NZ751418A (en) 2016-08-16 2023-04-28 Beigene Ltd Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof
CA3034326A1 (fr) 2016-08-19 2018-02-22 Beigene, Ltd. Utilisation d'une combinaison comprenant un inhibiteur de btk pour le traitement de cancers
WO2018217787A1 (fr) 2017-05-23 2018-11-29 Mei Pharma, Inc. Polythérapie
KR20200020902A (ko) 2017-06-26 2020-02-26 베이진 엘티디 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료
EP3668507A4 (fr) 2017-08-14 2021-05-12 MEI Pharma, Inc. Polythérapie
WO2019108795A1 (fr) 2017-11-29 2019-06-06 Beigene Switzerland Gmbh Traitement de lymphomes à cellules b indolentes ou agressives au moyen d'une combinaison comprenant des inhibiteurs de btk
US20220249491A1 (en) * 2019-06-10 2022-08-11 Beigene Switzerland Gmbh Oral solid tablet comprising bruton's tyrosine kinase inhibitor and preparation method therefor
CN113950327A (zh) * 2019-06-10 2022-01-18 百济神州瑞士有限责任公司 口服胶囊剂及其制备方法
CN110922409A (zh) * 2019-12-19 2020-03-27 武汉九州钰民医药科技有限公司 制备btk抑制剂泽布替尼的方法
KR20210115375A (ko) * 2020-03-12 2021-09-27 보령제약 주식회사 Pi3 키나아제 저해제 및 btk 저해제를 포함하는 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2608742C2 (ru) * 2011-03-28 2017-01-23 ЭмИАй ФАРМА, ИНК. (альфа-замещенные аралкиламино- и гетероарилалкиламино)пиримидинил- и 1, 3, 5-триазинилбензимидазолы, их фармацевтические композиции и их применение в лечении пролиферативных заболеваний
US20160287592A1 (en) * 2013-04-08 2016-10-06 Pharmacyclics Llc Ibrutinib combination therapy
KR20160093062A (ko) * 2013-12-05 2016-08-05 아세르타 파마. 비.브이. Pi3k 억제제 및 btk 억제제의 치료적 조합
TW201613644A (en) * 2014-06-17 2016-04-16 Acerta Pharma Bv Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, and/or a JAK-2 inhibitor
US20170231995A1 (en) * 2014-08-11 2017-08-17 Acerta Pharma B.V. BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment

Also Published As

Publication number Publication date
JP2021517116A (ja) 2021-07-15
WO2019183226A1 (fr) 2019-09-26
KR20200135439A (ko) 2020-12-02
CA3093847A1 (fr) 2019-09-26
TW202002983A (zh) 2020-01-16
EA202092154A1 (ru) 2021-03-22
EP3768258A1 (fr) 2021-01-27
BR112020019082A2 (pt) 2020-12-29
IL277336A (en) 2020-10-29
SG11202009137PA (en) 2020-10-29
US20210000838A1 (en) 2021-01-07
ZA202005661B (en) 2023-05-31
CN112165939A (zh) 2021-01-01
MX2020009773A (es) 2020-10-08
AU2019238207A1 (en) 2020-10-01
EP3768258A4 (fr) 2022-01-12

Similar Documents

Publication Publication Date Title
MA52090A (fr) Polythérapie
MA47676A (fr) Polythérapie
MA46285A (fr) Polythérapie
MA49921A (fr) Polythérapie
MA56057A (fr) Polythérapie
DK3752258T3 (da) Trampolin
DK3587968T3 (da) Fluidsystem
MA49925A (fr) Claie
DE112019000442A5 (de) Ringtilgereinrichtung
NO20181678A1 (no) Rissanviser
JP1628555S (ja) たい焼
JP1628556S (ja) たい焼
ES1218724Y (es) Terrario
ES1224156Y (es) Ecobolsera
UA38633S (uk) Електролобзик
UA38598S (uk) Пневмофарбопульт
UA38836S (uk) Термокухоль
UA38581S (uk) Термокухоль
UA38585S (uk) Електролобзик
UA38632S (uk) Електролобзик
UA38411S (uk) Термокухоль
UA38582S (uk) Термокухоль
UA38612S (uk) Електролобзик
UA38602S (uk) Термокухоль
UA38606S (uk) Електролобзик